BioHarvest plans Tel Aviv listing, trading Sept. 8, 2026

BioHarvest Sciences moves to dual list on the Tel Aviv Stock Exchange, registering existing and potential equity for TASE trading alongside Nasdaq.

Rhea-AI Filing Summary

BioHarvest Sciences Inc. (BHST) plans to become dual-listed by offering its ordinary shares for trading on the Tel Aviv Stock Exchange in addition to the Nasdaq Capital Market. Trading on the TASE is expected to begin on September 8, 2026, subject to completion of the listing process.

The company has requested TASE registration of all securities eligible to trade there, including 22,667,842 outstanding common shares, up to 4,516,021 common shares tied to its Equity Incentive Plan, and 610,742 common shares issuable upon exercise of investor warrants. Any future issuance and listing of additional common shares will require TASE approval.

Key Figures

Outstanding common shares: 22,667,842 shares Equity Incentive Plan pool: 4,516,021 shares Outstanding options: 2,564,876 options +4 more

7 metrics

Outstanding common shares 22,667,842 shares Common shares requested for TASE dual listing

Equity Incentive Plan pool 4,516,021 shares Maximum common shares available for issuance under the Equity Incentive Plan requested for TASE listing

Outstanding options 2,564,876 options Options to purchase common shares currently outstanding under the Equity Incentive Plan

Outstanding Restricted Share Units 269,521 RSUs Restricted Share Units currently outstanding under the Equity Incentive Plan

Shares remaining for future grants 1,681,624 shares Common shares remaining available for future grants under the Equity Incentive Plan

Warrant shares 610,742 shares Common shares issuable upon exercise of investor warrants requested for TASE listing

Expected TASE trading start date September 8, 2026 Date BioHarvest expects its shares to begin trading on the TASE

Key Terms

Dual listing, Tel Aviv Stock Exchange (TASE), Equity Incentive Plan, Restricted Shares Units, +2 more

6 terms

Dual listing market

"to become dual-listed for trade on both the Nasdaq and TASE markets"

A dual listing is when a company makes the same shares available on two different stock exchanges, often in different countries, so investors can buy and sell the same ownership stake in more than one market—like a shop opening branches in two cities that sell the same product. It matters to investors because it can widen the pool of buyers, make shares easier to trade, expose the stock to different currencies and rules, and create price differences or arbitrage opportunities that affect returns and risk.

Tel Aviv Stock Exchange (TASE) market

"offer its ordinary shares on the Tel Aviv Stock Exchange (TASE)"

Equity Incentive Plan financial

"available for future issuance to officers, employees and consultants of the Company pursuant to the Company’s Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Restricted Shares Units financial

"2,564,876 options to purchase Common Shares and 269,521 Restricted Shares Units are currently outstanding"

Botanical Synthesis technical

"a leader in Botanical Synthesis technology and sustainable plant-based molecule development"

Botanical synthesis is the lab-based creation or replication of plant-derived compounds, either by chemically building the molecules or by using engineered organisms to produce them, like recreating a recipe in a factory instead of harvesting from a garden. For investors it matters because it can lower costs, secure supply, protect patents, and affect regulatory review and market access for products that rely on consistent, scalable plant ingredients.

MAGNA Disclosure System regulatory

"All future EDGAR filings will simultaneously be filed on MAGNA Disclosure System"

FAQ

What did BioHarvest Sciences Inc. (BHST) announce in this Form 6-K?

BioHarvest Sciences announced its intention to become dual-listed, offering its ordinary shares for trading on the Tel Aviv Stock Exchange (TASE) in addition to the Nasdaq Capital Market, with trading on TASE expected to begin on September 8, 2026.

How many BioHarvest (BHST) common shares are outstanding and included in the TASE registration?

The company requested TASE registration of all 22,667,842 outstanding common shares with no par value in its capital, so these existing shares would be eligible for trading on both the Nasdaq Capital Market and the Tel Aviv Stock Exchange.

What equity incentive securities of BHST are covered by the TASE dual listing request?

The request covers up to 4,516,021 common shares under the Equity Incentive Plan, including 2,564,876 options, 269,521 Restricted Share Units, and 1,681,624 shares remaining for future grants, each convertible into one common share, subject to vesting and exercise.

Are BioHarvest (BHST) warrant shares included in the TASE registration request?

Yes. The company’s request includes 610,742 common shares issuable upon exercise of 610,742 warrants that were granted to investors, making these warrant shares eligible for trading on the Tel Aviv Stock Exchange when exercised.

Will BioHarvest (BHST) need approval for future share issuances on the TASE?

Yes. The company states that any future issuance and listing of additional common shares on the Tel Aviv Stock Exchange will be subject to the approval of the TASE.

Under which symbols will BioHarvest (BHST) trade after the dual listing?

BioHarvest’s common shares are listed on the Nasdaq Capital Market under the symbol BHST and are expected to trade on the TASE under the English symbol BHST and an alternative Hebrew symbol.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 03:21 PM Accepted by SEC EDGAR 09/03/2026 - 03:21 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission file number: 001-42389

BIOHARVEST SCIENCES INC.

(Exact name of Registrant as specified in its charter)

Not applicable

(Translation of Registrant’s name into English)

1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

☐ Form 20-F ☒ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

CONTENTS

On September 3, 2026, BioHarvest Sciences Inc. (the “Company”) issued a press release titled “BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)”. A copy of this press release is attached to this Form 6-K as Exhibit 99.1.

Thie 6-K is incorporated by reference into the Company’s registration statements on Form F-3 (File No, 333-289908) and Form S-8 ( File No 333-288882)

SUBMITTED HEREWITH

Exhibits:

Exhibit	Description
99.1	News Release dated September 3, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOHARVEST SCIENCES INC.
	(Registrant)
Date: September 3, 2026	/s/ David Ryan
	Name: David Ryan
	Title: Vice-President, Investor Relations & Secretary

BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)

Vancouver, British Columbia and Rehovot, Israel – September 3, 2026 – BioHarvest Sciences Inc. (Nasdaq: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development today announced its intention to offer its ordinary shares on the Tel Aviv Stock Exchange (TASE) and to become dual-listed for trade on both the Nasdaq and TASE markets.  BioHarvest expects its shares to begin trading on the TASE on September 8, 2026.

Dr Zaki Rakib, CEO of BioHarvest Sciences, commented, “BioHarvest is entering an exciting new phase of growth, built on the strength of our Botanical Synthesis platform and the commercial opportunities it is creating. As an Israeli-founded company with global ambitions, we believe a dual listing on the Tel Aviv Stock Exchange alongside Nasdaq is a natural step-broadening access to our shares and strengthening our connection with the Israeli investment community.”

Per the filed registration documents, the Company has requested to register all outstanding and potential future shares for dual listing on the TASE, including:

(1) all 22,667,842 outstanding common shares with no par value in the capital of the Company (“Common Shares”);

(2) up to 4,516,021 Common Shares available for future issuance to officers, employees and consultants of the Company pursuant to the Company’s Equity Incentive Plan, out of which 2,564,876 options to purchase Common Shares and 269,521 Restricted Shares Units are currently outstanding and 1,681,624 shares remaining available for future grants (upon exercise of options and Restricted Shares Units), all subject to vesting, and exercise for an equivalent number of Common Shares of the Company (1:1 ratio); and

(3) 610,742 Common Shares issuable upon exercise of 610,742 warrants granted to investors.

Any future issuance and listing of additional Common Shares will be subject to the approval of the TASE.

The Common Shares are listed for trading in the United States on the Nasdaq Capital Market. The shares are expected to trade on the TASE under the English symbol BHST and the alternative Hebrew symbol . All future EDGAR filings will simultaneously be filed on MAGNA Disclosure System.

About BioHarvest

BioHarvest (Nasdaq: BHST) (FSE: 8MV0) is a leader in Botanical Synthesis, leveraging its patented technology platform to grow plant-based compounds, without the need to grow the underlying plant. BioHarvest is leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions within two major business verticals; as a contract development and manufacturing organization (CDMO) on behalf of customers seeking novel plant-based compounds, and as a creator of proprietary nutraceutical health and wellness products based on its botanical synthesis technology. To learn more, please visit www.bioharvest.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on management’s current expectations, beliefs, and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. For the CDMO Services Business Unit, there is no assurance of additional future contracts, and readers are cautioned that increased revenue is not necessarily an increase in net income or profitability as costs will likely increase as well. There is no assurance that signed research agreements will proceed past a contracted stage, or that a developed molecule or compound will be commercialized or will generate royalties to the Company. Successful commercialization of any compound developed will be subject to consumer preferences, advertising budgets and other factors affecting market acceptance of new products which are uncertain and cannot be assured.

Readers are cautioned not to place undue reliance on forward-looking statements. The Company does not undertake any obligation to update forward-looking statements except as required by applicable law. Additional information is contained in the Company’s SEC filings, available at http://www.sec.gov.

Company Contact

Dave Ryan, VP Investor Relations

(604) 622-1186

info@bioharvest.com

Investor Relations Contact:

Chuck Padala, Managing Director

LifeSci Advisors

chuck@lifesciadvisors.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 NEWS RELEASE DATED SEPTEMBER 3, 2026 9.1 KB